The Effects of Infliximab Maintenance Therapy on Health-Related Quality of Life

American Journal of Gastroenterology

Volumn 98, Issue 10, 2003, Pages 2232-2238

  Feagan, Brian G ^a   Yan, Songkai ^b   Bala, Mohan ^b   Bao, Weihang ^b   Lichtenstein, Gary R ^b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRANULOMATOUS INFLAMMATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK BENEFIT ANALYSIS; SCORING SYSTEM;

EID: 0142214828     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07674.x     Document Type: Article

References (21)

1. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
2. Feagan BG, McDonald JWD. Methotrexate for Crohn's disease. N Engl J Med 1995;333:600-1 (letter).
3. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
4. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF anti-body. Mol Immunol 1993;30:1443-53.
5. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163: 1521-8.
6. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
7. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002;8:237-43.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al, and the ACCENT I Study Group. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359: 1541-9.
9. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
10. Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997;3:265-76.
11. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
12. Feagan BG, McDonald J, Rochon J, et al, for the Canadian Crohn's Prevention Trial Investigators. Low-dose cyclosporine for treatment of Crohn's disease. N Engl J Med 1994;330: 1846-51.
13. Feagan BG, Rochon J, Fedorak RN, et al, for the North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332: 292-7.
14. Greenberg GR, Feagan BG, Martin F, et al, for the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41.
15. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): Conceptual framework and item selection. Med Care 1992;30:473-83.
16. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: A user's manual. Boston: The Health Institute, 1994.
17. Padierna A, Quintana JM, Arostegui I, et al. Quality of life in patients with inflammatory bowel disease. Annual Meeting of the International Society for Technological Assessment in Health Care 1997;13:145.
18. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
19. Dantzer R. Cytokine-induced sickness behavior: Mechanisms and implications. Ann NY Acad Sci 2001;933:222-34.
20. Anisman H, Merali Z. Cytokines, stress, and depressive illness. Brain Behav Immunol 2002;16:513-24.
21. O'Connor TM, O'Halloran DJ, Shanahan F. The stress response and the hypothalamic-pituitary-adrenal axis: From molecule to melancholia. Q J Med 2000;93:323-33.